December 9, 2019
WALTHAM, Mass.–(BUSINESS WIRE)–TScan Therapeutics recognizes its co-founders, Lea Hachigian Ph.D. and Tomasz Kula Ph.D., who were honored as healthcare pioneers in the Forbes 30 Under 30 list Class of 2020. The Forbes 30 Under 30 lists are awarded annually and are determined by a group of recognized healthcare leaders.
“The entire TScan team congratulates Lea and Tomasz for this well-deserved honor. TScan’s core T-cell receptor (TCR) discovery technology was developed by Tomasz in the laboratory of Lasker Award-winner Dr Stephen Elledge at Harvard Medical School. Tomasz and Lea then founded TScan to refine the technology and Lea led the charge in formulating the company’s strategy to generate novel immunotherapies based on the technology.
“Tomasz and Lea’s efforts are the foundation for TScan’s great potential to truly unlock the power of immunotherapy. TScan’s unique high-throughput, whole-genome and unbiased technology to simultaneously discover the targets of tumor-reactive TCRs and accurately determine any potential off-target effects helps resolve the two greatest obstacles to advancing novel T cell-based immuno-oncology therapies,” continued David P. Southwell, President and Chief Executive Officer.
The entire 2020 Forbes 30 Under 30 Healthcare list can be found here.
About TScan Therapeutics
TScan designs therapies that reprogram a patient’s own T cells to recognize and fight their cancer using naturally-occurring TCRs that find and destroy shared cancer targets. The TScan technology process allows TCRs to be scanned against target antigens in a genome-wide, high-throughput, and unbiased fashion. TScan is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors, and has already discovered, through this process, novel antigens from TCRs, novel TCRs from known antigens, and previously uncharacterized off-targets of known TCRs.
For more information, please visit www.tscan.com.